FDA approval for ILUVIEN® in DME strengthens Alimera Sciences in global ophthalmology arena

Alimera Sciences Inc., a pharmaceutical company that specialises in the research, development and commercialisation of prescription ophthalmic pharmaceuticals, today announced that the US Food and Drug Administration (FDA) has approved ILUVIEN® for the treatment of diabetic macular oedema (DME). This comes nearly 18 months after the treatment became available in the UK and Germany, having received an approvable response via the European Decentralised Procedure in February 2012.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Industry News Diabetes Ophthalmology diabetic macular oedema ILUVIEN intravitreal implant Latest News Source Type: news